litlas
ログインアカウント作成

Peter J. Goadsby

1982–2025 年に発表

別表記
Peter J Goadsby
432
論文数
78,660
被引用数
146
h 指数
417
i10 指数

被引用数

Peter J. Goadsby の年別被引用数1985 年: 被引用 1 件1986 年: 被引用 2 件1987 年: 被引用 2 件1988 年: 被引用 6 件1989 年: 被引用 9 件1990 年: 被引用 12 件1991 年: 被引用 21 件1992 年: 被引用 20 件1993 年: 被引用 41 件1994 年: 被引用 43 件1995 年: 被引用 52 件1996 年: 被引用 60 件1997 年: 被引用 135 件1998 年: 被引用 79 件1999 年: 被引用 118 件2000 年: 被引用 121 件2001 年: 被引用 178 件2002 年: 被引用 256 件2003 年: 被引用 273 件2004 年: 被引用 417 件2005 年: 被引用 400 件2006 年: 被引用 493 件2007 年: 被引用 419 件2008 年: 被引用 531 件2009 年: 被引用 742 件2010 年: 被引用 551 件2011 年: 被引用 456 件2012 年: 被引用 466 件2013 年: 被引用 554 件2014 年: 被引用 460 件2015 年: 被引用 435 件2016 年: 被引用 392 件2017 年: 被引用 663 件2018 年: 被引用 609 件2019 年: 被引用 2,158 件2020 年: 被引用 2,180 件2021 年: 被引用 2,101 件2022 年: 被引用 1,791 件2023 年: 被引用 1,588 件2024 年: 被引用 2,510 件2025 年: 被引用 1,161 件2026 年: 被引用 24 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,011 件、この内訳の 24.7%イギリス: 引用元論文 1,076 件、この内訳の 8.8%イタリア: 引用元論文 921 件、この内訳の 7.5%ドイツ: 引用元論文 791 件、この内訳の 6.5%デンマーク: 引用元論文 604 件、この内訳の 4.9%中国: 引用元論文 598 件、この内訳の 4.9%スペイン: 引用元論文 413 件、この内訳の 3.4%オランダ: 引用元論文 386 件、この内訳の 3.2%カナダ: 引用元論文 315 件、この内訳の 2.6%フランス: 引用元論文 279 件、この内訳の 2.3%オーストラリア: 引用元論文 257 件、この内訳の 2.1%スイス: 引用元論文 224 件、この内訳の 1.8%
0%24.7%その他 27.3%

機関

分野

  • Medicine82.7%
  • Neuroscience11%
  • Biochemistry, Genetics and Molecular Biology2.4%
  • Psychology0.9%
  • Pharmacology, Toxicology and Pharmaceutics0.7%
  • Health Professions0.7%
  • その他1.6%

トピック

  • Migraine and Headache Studies24%
  • Trigeminal Neuralgia and Treatments6.6%
  • Neurological Complications and Syndromes4.1%
  • Sympathectomy and Hyperhidrosis Treatments3%
  • Traumatic Brain Injury Research2.9%
  • Vestibular and auditory disorders2.8%
  • その他56.6%

共著者

全論文

検索で開く
  1. Pathophysiology of Migraine: A Disorder of Sensory Processing

    著者: Peter J. Goadsby, Philip R. Holland, Margarida Martins-Oliveira, Jan Hoffmann, Christoph J. Schankin, Simon Akerman - Physiological Reviews 2017 被引用: 1,968

  2. Migraine

    著者: Michel D. Ferrari, Peter J. Goadsby, Rami Burstein, Tobias Kurth, Cenk Ayata, Andrew Charles, Messoud Ashina, Arn M. J. M. van den Maagdenberg, David W. Dodick - Nature Reviews Disease Primers 2022 被引用: 522

  3. Atogepant for the Preventive Treatment of Migraine

    著者: Jessica Ailani, Richard B. Lipton, Peter J. Goadsby, Hua Guo, Rosa Miceli, Lawrence Severt, Michelle Finnegan, Joel M. Trugman - New England Journal of Medicine 2021 被引用: 310

  4. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial

    著者: Robert Croop, Richard B. Lipton, David Kudrow, David Stock, Lisa Kamen, Charles M. Conway, Elyse Stock, Vladimir Coric, Peter J. Goadsby - The Lancet 2020 被引用: 351

  5. A Controlled Trial of Erenumab for Episodic Migraine

    著者: Peter J. Goadsby, Uwe Reuter, Yngve Hallström, Gregor Broessner, Jo Bonner, Feng Zhang, Sandhya Sapra, Hernàn Picard, Daniel D. Mikol, Robert Lenz - New England Journal of Medicine 2017 被引用: 948

  6. Migraine: disease characterisation, biomarkers, and precision medicine

    著者: Messoud Ashina, Gisela M. Terwindt, Mohammad Al‐Mahdi Al‐Karagholi, Irene de Boer, Mi Ji Lee, Debbie L. Hay, Laura Schulte, Nouchine Hadjikhani, Alexandra J. Sinclair, Håkan Ashina, Todd J. Schwedt, Peter J. Goadsby - The Lancet 2021 被引用: 370

  7. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache

    著者: Peter J. Goadsby, Lars Edvinsson, Rolf Ekman - Annals of Neurology 1990 被引用: 1,610

  8. Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine

    著者: Richard B. Lipton, Robert Croop, Elyse Stock, David Stock, Beth Morris, Marianne Frost, Gene M. Dubowchik, Charles M. Conway, Vladimir Coric, Peter J. Goadsby - New England Journal of Medicine 2019 被引用: 396

  9. Fremanezumab for the Preventive Treatment of Chronic Migraine

    著者: Stephen D. Silberstein, David W. Dodick, Marcelo E. Bigal, Paul Yeung, Peter J. Goadsby, Tricia Blankenbiller, Melissa Grozinski‐Wolff, Ronghua Yang, Yuju Ma, Ernesto Aycardi - New England Journal of Medicine 2017 被引用: 803

  10. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial

    著者: Robert Croop, Peter J. Goadsby, David Stock, Charles M. Conway, Micaela Forshaw, Elyse Stock, Vladimir Coric, Richard B. Lipton - The Lancet 2019 被引用: 392

  11. Galcanezumab in chronic migraine

    著者: Holland C. Detke, Peter J. Goadsby, Shufang Wang, Deborah I. Friedman, Katherine J. Selzler, Sheena K. Aurora - Neurology 2018 被引用: 578

  12. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: Patricia Pozo‐Rosich, Jessica Ailani, Messoud Ashina, Peter J. Goadsby, Richard B. Lipton, Uwe Reuter, Hua Guo, Brittany Schwefel, Kaifeng Lu, Ramesh Boinpally, Rosa Miceli, Rosa De Abreu Ferreira, Emily McCusker, Sung Yun Yu, Lawrence Severt, Michelle Finnegan, Joel M. Trugman - The Lancet 2023 被引用: 133

  13. Efficacy and safety of eptinezumab in patients with chronic migraine

    著者: Richard B. Lipton, Peter J. Goadsby, Jeff Smith, Barbara Schaeffler, David M. Biondi, Joe Hirman, Susan Pederson, Brent Allan, Roger Cady - Neurology 2020 被引用: 392

  14. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial

    著者: Richard B. Lipton, Robert Croop, David Stock, Jennifer Madonia, Micaela Forshaw, Meghan Lovegren, Linda Mosher, Vladimir Coric, Peter J. Goadsby - The Lancet Neurology 2023 被引用: 145

  15. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine

    著者: David W. Dodick, Stephen D. Silberstein, Marcelo E. Bigal, Paul Yeung, Peter J. Goadsby, Tricia Blankenbiller, Melissa Grozinski‐Wolff, Ronghua Yang, Yuju Ma, Ernesto Aycardi - JAMA 2018 被引用: 573

  16. The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats

    著者: Peter J. Goadsby, Lars Edvinsson - Annals of Neurology 1993 被引用: 1,162

  17. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial

    著者: Peter J. Goadsby, David W. Dodick, Jessica Ailani, Joel M. Trugman, Michelle Finnegan, Kaifeng Lu, Armin Szegedi - The Lancet Neurology 2020 被引用: 230

  18. Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update

    著者: Andrew Charles, Kathleen B. Digre, Peter J. Goadsby, Matthew S. Robbins, Andrew D. Hershey, The American Headache Society - Headache The Journal of Head and Face Pain 2024 被引用: 195

  19. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study

    著者: Uwe Reuter, Peter J. Goadsby, Michel Lantéri‐Minet, Shihua Wen, Peggy Hours-Zesiger, Michel D. Ferrari, Jan Klatt - The Lancet 2018 被引用: 470

  20. Migraine: from pathophysiology to treatment

    著者: Francesca Puledda, Elisa Silva, Kanokrat Suwanlaong, Peter J. Goadsby - Journal of Neurology 2023 被引用: 178

  21. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA

    著者: David W. Dodick, Peter J. Goadsby, Todd J. Schwedt, Richard B. Lipton, Chengcheng Liu, Kaifeng Lu, Sung Yun Yu, Lawrence Severt, Michelle Finnegan, Joel M. Trugman - The Lancet 2023 被引用: 85

  22. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults

    著者: Cristina Tassorelli, Hans‐Christoph Diener, David W. Dodick, Stephen D. Silberstein, Richard B. Lipton, Messoud Ashina, Werner J. Becker, Michel D. Ferrari, Peter J. Goadsby, Patricia Pozo‐Rosich, Shuu‐Jiun Wang - Cephalalgia 2018 被引用: 385

  23. Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS)

    著者: AM Blumenfeld, SF Varon, TK Wilcox, DC Buse, AK Kawata, AN Manack, Peter J. Goadsby, RB Lipton - Cephalalgia 2010 被引用: 644

  24. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks

    著者: Farooq Maniyar, Till Sprenger, Teshamae Monteith, Christoph J. Schankin, Peter J. Goadsby - Brain 2013 被引用: 494